Gov. Kathy Hochul announced plans to build a $430 million New York BioGenesis Park — a cell and gene therapy lab — in Lake ...
The pharma market shows promise as gene therapy gains momentum through rapid advancements that address complex diseases and ...
The team has developed synthetic 'DNA switches' that can control genes in certain cells. It's believed the technology could ...
The significance of this is that it brings about the ability to obtain FDA approval for this AAV gene therapy without the need to run a phase 3 study. Even better, it has another positive worth ...
Researchers have used artificial intelligence to design thousands of new DNA switches that can precisely control the expression of a gene in different cell types. Their new approach opens the ...
Researchers used AI to design thousands of new DNA switches that can precisely control the expression of a gene in different cell types.
By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...
The regulator agreed to allow Sangamo Therapeutics to use data to seek accelerated approval for its Fabry gene therapy ...
RNA editing has picked up steam in recent years as a potentially safer alternative to gene editing to treat genetic diseases.
Eye drug maker Ocuphire Pharma is acquiring gene therapy developer Opus Genetics in an all-stock transaction that will see ...
The Japanese government, industry and academia are deliberating health care policies and initiatives to boost Japan’s role in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback